header logo image


Page 25«..1020..24252627..3040..»

Archive for the ‘Regenerative Medicine’ Category

Leading the Movement Towards Direct Cell Conversion: An Interview With Mogrify – Technology Networks

Thursday, April 16th, 2020

Biotech company Mogrify is deploying its proprietary direct cellular conversion technology to develop cell therapies in a variety of disease areas, including auto-immune, musculoskeletal, respiratory diseases and in cancer immunotherapy.The platform utilizes data from next-generation sequencing and cellular networks to identify transcription factors or small molecules required to directly convert a cell, addressing key challenges that are typically associated with the safety and efficacy of cell therapies.Technology Networks recently spoke with Joe Foster, COO, Mogrify, to learn more about the platform, the challenges encountered in developing cell therapies, and to gain Mogrify's insights on the future of this exciting research space.Molly Campbell (MC): What were some of the major highlights for Mogrify in 2019?Joe Foster (JF): In the past year, Mogrify has solidified its reputation as a pioneer in the expanding field of cell therapy. Using a systematic, data-driven approach, our innovative cell conversion platform addresses many of the challenges impeding systematic discovery, process development and the manufacturing processes.At an operational level, Mogrify has seen unprecedented growth in the last year, with emphasis on world-class science. We have established a leadership team with unparalleled track records, including the appointment of Dr Darrin M. Disley OBE, as CEO and Dr Jane Osbourn OBE, as Chair. Looking forward and with plans to boost our team to 70 individuals working across all disciplines, Mogrify has also moved operations to the new Bio-Innovation Centre in Cambridge, giving our team access to state-of-the-art facilities to continue their work in developing novel approaches to cell therapy.Mogrify received MSDs Innovation Award at the 15th Annual Scrip Awards, in acknowledgement of our potential to transform future cell therapies. Dr Jane Osbourn OBE was also the first female to win the Lifetime Achievement Award, recognizing her significant contributions to the biotech industry. Mogrifys significant fundraising success was also marked at the prestigious European Lifestars Awards, which celebrates excellence in the life science industry. Here, Mogrify was recognized as the Seed Stage Finance Raise of the Year.MC: In Mogrify's opinion, what key trends can we expect to see in the cell therapy space in 2020?JF: Many of the current approaches to cell therapy involve first converting cells back into a stem cell-like stateinduced pluripotent stem cellsbefore then converting them into the cell type required.Mogrify plans to lead the movement towards direct cell conversion, or transdifferentiation, where cells can be transformed from one cell type to another, without having to go through an intermediate pluripotent stage. Direct conversion of cells would enhance the speed of cell therapy development, as cells do not need to use traditional developmental pathways to reach a mature state.

Another bottleneck in the delivery of cell therapies is that most approaches rely on autologous transplants, which are carried out using patient-derived cells. Future innovations are moving towards using allogeneic therapies, where the cells used for therapy are derived from a healthy donor. Such advances are paving the way towards the development of universal donor cells, which would turn cell therapies into off-the-shelf treatments, enhancing the scale and accessibility of the treatments.

Finally, cell therapy methods are likely to move from ex vivo approaches (where cells are isolated from the patient, reprogrammed, and delivered back into the patient), to in vivo approaches, where cell therapies are delivered directly to the recipient, for example, through the use of small molecules present in a reprogramming cocktail or direct gene editing. In vivo technologies would, therefore, be able to reprogram cells directly in living humans, expanding the scope of cell therapy in a clinical setting. Overall, future cell therapies will have the capacity to be more effective, safer, and widely accessible.

MC: What are the key challenges that currently exist when developing and testing cell therapies? How does Mogrify hope to overcome such challenges?JF: The biggest challenges in producing cell therapies surround the efficacy, safety profile, and scalability of clinical treatment regimes. To make treatments safer, delivered cells must bypass the host immune system. This can be achieved with autologous therapy, but comes at the cost of scale and efficiency, as the patients cells need to be extracted, cultured, and reprogrammed before treatment can be delivered. Genetic engineering technologies (such as CRISPR/Cas9) that can be employed to remove the antigenic potential of allogeneic cell therapies (e.g. CAR-T) can be used in conjunction with such treatments, but this brings an additional layer of complication.Another difficulty comes from the technical challenges associated with generating, culturing, and expanding the required cells. In theory, any cell type can be derived from pluripotent cells. However, determining precisely how to generate any cell from pluripotent cells is conceptually and practically complex. Each cell type would require a distinct combination of transcription factors (or small molecules) and optimized culture conditions to ensure robust conversion into the desired phenotype. These technical challenges are associated with slow progress and poor efficiency in deriving reliable therapeutic cells.

Mogrify aims to tackle these hurdles with solutions involving big data, computational predictions, and bioinformatics. Mogrifys proprietary algorithm uses next generation sequencing data to predict the combination of transcription factors necessary to reliably convert any cell type into another cell type. Mogrifys technology provides a framework for direct cell conversion, and can also identify the best culture conditions to ensure that the cell populations remain stable and viable. This greatly improves cell therapy efficiency, as mature cells are created without the often arduous and imprecise process of differentiating cells from pluripotency.

Mogrifys technology is also compatible with in vivo cell therapies, as it can identify a combination of small molecules that will drive the necessary transcriptional networks to create the cells of choice. Therefore, Mogrifys technology can also be applied to overcome safety issues associated with allogeneic ex vivo approaches, and has the potential to greatly enhance the scale at which cell therapies can be delivered.MC: Are you able to tell us more about the latest developments in Mogrify's pipeline?JF: Currently, Mogrify is focused on applying the platform to musculoskeletal disorders, cancer immunotherapy, and auto-immune, ocular and respiratory diseases. Specifically, Mogrify is committed to identifying opportunities in regenerative medicine contexts, where direct cell conversion could have strong therapeutic potential.The current lead musculoskeletal program is in the development of chondrocytes for the treatment of cartilage defects and osteoarthritis. Mogrifys platform identified a cocktail of small molecules that successfully drives the conversion of fibroblast cells to chondrocytes, which has been proven to form functional hyaline cartilage in vitro. This can even be performed using an allogeneic approach without the need for gene editing (as the cartilage is immunopriviliged). Thus, it represents an opportunity for an off-the-shelf therapy that could be a relatively inexpensive and accessible treatment. At present, this treatment is in pre-clinical stages, and has a powerful potential for success in regenerative cartilage therapy. Similarly, an in vivo method of transdifferentiating osteoarthritic chondrocytes to healthy cells is being investigated in ongoing studies using a cocktail of small molecules.

Joe Foster, COO, Mogrify was speaking to Molly Campbell, Science Writer, Technology Networks.

Here is the original post:
Leading the Movement Towards Direct Cell Conversion: An Interview With Mogrify - Technology Networks

Read More...

Community resilience is facing Its greatest threat, and colleges are helping | Opinion – pennlive.com

Thursday, April 16th, 2020

Throughout history, the nations colleges and universities have set the foundation for innovation and social change. Weve uncovered the secrets of DNA. Weve unleashed bioengineering. We have harnessed intellectual power to create new technologyoften through the partnerships between land grant colleges and local industries and agriculturebringing the latest science to where it was needed. And we have done it all while demanding intellectual rigor and a sharp focus on the common good for society.

At Boston University, the Center for Regenerative Medicine at BUs Medical Center, alerted by colleagues at the University of Washington in Seattle, coordinated with MITs Broad Institute as well as Harvard to produce a test for the virus with a turn around time of within 24 hours. More than 50 volunteered in this round the clock effort. Testing is now underway. Rutgers University has launched its own virus testing program. Its RUCDR Infinite Biologicsa part of the Universitys Human Genetics Institute of New Jerseyis now capable of testing tens of thousands.

Tiny Bay Mills Community College, a Michigan tribal college of fewer than 500 students, has used 3-D technology to design and now produce 1,000 face masks for first responders every week.

Institutions of higher education, large and small, can and do play a significant role in serving our country and our world at this critical moment in history. But our work starts at home. Whats required is a community approach, as local areas are impacted in distinct ways while this crisis unfolds.

I learned the power of community response to overwhelming challenges at the American University of Nigeria. I served there as president when Boko Haram began to surge near the campus and federal assistance was nowhere to be found. The university brought the community together and kept the terrorist group at bay and fed refugees.

Drawing on that experience, when I arrived at Dickinson three years ago, I immediately began to gather with community members to identify their most pressing issues and to connect them with college resources. What started out as a dozen people has now grown to more than 50 representing nearly every sectornonprofits, school districts, health care, government and business. We are meeting remotely in the age of COVID-19, but the relationships we have built have allowed us to respond quickly in a coordinated manner to the communitys growing needs.

Working with Carlisle Borough, the Chamber of Commerce and Community CARES partnered to convert the Stuart Community Center into a shelter for the homeless. UPMC Carlisle anticipated a potential need for housing and shelter for its exhausted medical workers; Dickinson stepped up and agreed to make space available in our vacated residence halls. Local businesses needed an online presence to offer goods and services, but lacked the know-how; Dickinson students are developing e-commerce websites for those businesses. Our organic farm is supplying much-needed fresh produce for the community.

Colleges areand should beat the epicenter of community responses to COVID. They can and should be the assembly point for community action. Its imperative that colleges start building or strengthening relationships with leaders in their communities now, to help in recovery and before the next crisis or disaster occurs.

When students return to class, they will return to communities that have changed in myriad ways. The old ideas, approaches and leadership simply wont do. Our students and young people are the ones we will need to help us with the necessary reconstruction. Those students will rely on the knowledge and problem-solving skills our institutions of higher learning should be providing.

In these difficult times, the country must demand much of its colleges and universities. Communities must know that we are in the trenches with you, and that we are all of us prepared to do more. When students return to our campuses we should work together to build a program of national service. This is how we will rebuild America and prepare the next generation for more unprecedented challenges.

Margee M. Ensign is president of Dickinson College, in Carlisle. Previously, Ensign served as president of the American University of Nigeria, where she developed aid and relief programs for hundreds of thousands of internally displaced people fleeing Boko Haram.

Continue reading here:
Community resilience is facing Its greatest threat, and colleges are helping | Opinion - pennlive.com

Read More...

ACRO Biomedical’s Proprietary Technology Leads the World with Patents from Taiwan, Japan, USA, and Korea – Yahoo Finance

Thursday, April 16th, 2020

TAIPEI, April 16, 2020 /PRNewswire/ -- ACRO Biomedical Co., Ltd., the first company in the world to utilize "supercritical CO2 extraction technology" on cleansing animal tissues and organs, is gradually showing impressive results on the global patent map. In 2019, ACRO acquired two patents from Japan. One for the decellularized cartilage graft, and another for the decellularized cornea. The great news continues with ACRO acquiring patents from the USA and Korea successively for the decellularized cornea in March 2020.

ACRO has acquired patents from Taiwan, the USA, Japan, and Korea for the preparation of acellular corneas by utilizing supercritical CO2 extraction technology. Patents from India, EU, Hong Kong, andmainland China are also on their way. The wish to benefit patients around the world with damaged cornea is very promising.

The CEO of ACRO Biomedical, DJ Hsieh, said that the traditional way to utilize supercritical CO2 extraction technology is to extract herbal medicine and essential oil. After many years of research and development, ACRO has successfully utilized the technology on cleansing animal tissues and organs including skin, bone, cartilage, cornea, blood vessel, nerve, heart, kidney, liver, pancreas, and brain. Many of the products have received approval from USFDA, Singapore, Vietnam, Philippines, and Taiwan FDA. Furthermore, ACRO has licensed out Collagen Ophthalmic Matrix to Oculus BioMed from Australia, and also signed an exclusive strategic partnership agreement with Marubeni Corporation from Japan, laying the foundation for the global market.

The advantages of ACRO's technology application are its high efficiency, low cost, time-saving, and when compared with other products of the same type that are decellularized with acid-base solutions or organic solvents, it greatly reduces the chance of allergy and immune rejection. It is a great help for the future development of the global regenerative medicine.

SOURCE ACRO Biomedical Co., Ltd.

See the original post:
ACRO Biomedical's Proprietary Technology Leads the World with Patents from Taiwan, Japan, USA, and Korea - Yahoo Finance

Read More...

New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion’s SEP-363856 for the Treatment of Schizophrenia – PharmaLive

Thursday, April 16th, 2020

In this study, once-daily, flexible-dose (50-75 mg) treatment with SEP-363856 demonstrated a statistically significant and clinically meaningful improvement in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo after four weeks of treatment (-17.2 vs. -9.7, respectively; p=0.001). Patients treated with SEP-363856 also showed improvement in the overall severity of illness as assessed by the Clinical Global Impression Scale Severity (CGI-S) (p<0.001). In addition, improvement was observed in all major PANSS (positive, negative and general psychopathology) subscales (p<0.02). SEP-363856 was well tolerated throughout the study and the overall discontinuation rate was comparable for SEP-363856 and placebo.1

These data represent an exciting step forward in schizophrenia research. The steps that led to identifying this new mechanism of action, targeting TAAR1, were very novel and they reflected a courageous and innovative approach by Sunovion to identifying new ways to treat schizophrenia, said John Krystal, M.D., Chair of Psychiatry and Co-Director, Yale Center for Clinical Investigation at Yale School of Medicine and co-author of the NEJM publication. For the last 60 years, antipsychotics that bind to dopamine receptors have been the standard of care, despite their side effect profile. It is my hope that these results for SEP-363856 support a new schizophrenia treatment for people who have been diagnosed with this serious mental health condition. SEP-363856 could have a big impact on people with schizophrenia, their families, and on the public health burden posed by schizophrenia.

SEP-363856 is a novel trace amine-associated receptor 1 (TAAR1) agonist with serotonin 1A (5-HT1A) agonist activity that is being evaluated in patients with schizophrenia. SEP-363856 does not bind to dopamine 2 (D2) or serotonin 2A (5-HT2A) receptors, which are thought to mediate the effects of currently available atypical antipsychotic medicines. SEP-363856 is being studied in the DIAMOND (Developing Innovative Approaches for Mental Disorders) Phase 3 global development program for schizophrenia with additional indications under consideration. The U.S. FDA granted Breakthrough Therapy Designation for SEP-363856 for the treatment of schizophrenia in May 2019.

Publication of these findings in the New England Journal of Medicine demonstrates the potential of SEP-363856 to be the first TAAR1 agonist for the treatment of schizophrenia, said Kenneth Koblan, PhD, Chief Scientific Officer of Sunovion. This innovative approach to the treatment of schizophrenia may provide a completely new option for the 23 million people worldwide who live with this serious mental health condition. Sunovion is committed to developing new treatment options for these patients and continuing to study SEP-363856 to further evaluate its clinical benefit in schizophrenia and other neuropsychiatric conditions.

As noted in the NEJM publication, in the six-month, open-label extension study, SEP-363856 demonstrated continued improvement across efficacy measures, including the PANSS total score, the CGI-S score, and the Brief Negative Symptom Scale (BNSS) total score and appeared to be safe and well-tolerated.

About SEP-363856 SEP-363856 is a TAAR1 agonist with 5-HT1A agonist activity that is under investigation for the treatment of schizophrenia and other psychiatric conditions. Sunovion discovered SEP-363856 in collaboration with PsychoGenics based in part on a mechanism-independent approach using the in vivo phenotypic SmartCube platform and associated artificial intelligence algorithms. SEP-363856 is being studied in a global Phase 3 development program for schizophrenia (DIAMOND) with additional indications under consideration. The U.S. FDA granted Breakthrough Therapy Designation for SEP-363856 for schizophrenia in May 2019.

About Schizophrenia Schizophrenia is a chronic, serious and often severely disabling brain disorder that affects more than 23 million people worldwide2 and approximately one in 100 adults (about 2.4 million people) in the United States.3 It is characterized by positive symptoms, such as hallucinations, delusions and disorganized thinking as well as negative symptoms, such as lack of emotion, social withdrawal, lack of spontaneity and cognitive impairment that includes problems with memory, attention and the ability to plan, organize and make decisions.2

About Sunovion Pharmaceuticals Inc. (Sunovion) Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovions vision is to lead the way to a healthier world. The companys spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.

Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional information can be found on the companys websites: http://www.sunovion.com, http://www.sunovion.eu and http://www.sunovion.ca. Connect with Sunovion on Twitter, LinkedIn, Facebook and YouTube.

About Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma is among the top-10 listed pharmaceutical companies in Japan, operating globally in major pharmaceutical markets, including Japan, the U.S., China, and the European Union. Sumitomo Dainippon Pharma aims to create innovative pharmaceutical products in the Psychiatry & Neurology area, the Oncology area and Regenerative medicine/Cell therapy field, which have been designated as the focus therapeutic areas. Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 6,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at https://www.ds-pharma.com.

SUNOVION is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd. 2020 Sunovion Pharmaceuticals Inc. All rights reserved.

For a copy of this release, visit Sunovions website at http://www.sunovion.com

References

1 Koblan, K., Kent, J., Hopkins, S., Krystal, J., Cheng, H., Goldman, R., Loebel, A., A non-D2 Binding Drug for the Treatment of Schizophrenia. New England Journal of Medicine. April 16, 2020, Vol. 382, Issue 16, p. 1497-1506. Available online: https://www.nejm.org/doi/full/10.1056/NEJMoa1911772. Accessed April 2020. 2 World Health Organization. Mental Disorders. [Internet]. Available from:https://www.who.int/news-room/fact-sheets/detail/mental-disorders. Accessed September 2018. 3 National Institute of Mental Health. Schizophrenia. [Internet]. Available from: https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml. Accessed September 2018.

Follow this link:
New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion's SEP-363856 for the Treatment of Schizophrenia - PharmaLive

Read More...

Global Regenerative Medicine Market : Industry Analysis and Forecast (2019-2026): By Type, Application and Region. – Publicist360

Thursday, April 16th, 2020

Global Regenerative Medicine Marketwas valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at a XX %CAGR of around 24.3% during a forecast period.

Regenerative medicine is an interdisciplinary field of medicine that is used for developing methods to grow, replace or repair diseased or damaged cells, organs, and tissues. Regenerative medicine contains the generation and use of therapeutic stem cells, tissue engineering and the production of artificial organs.

The report covers all the trends and technologies playing a major role in the growth of the regenerative medicine market over the forecast period. It highlights the drivers, restraints, and opportunities expected to influence market growth during 2019-2026.

Global Regenerative Medicine Market

Regenerative medicines are expected to have a major impact on healthcare to treat specific indications and chronic conditions. Therefore, a high prevalence of cancer, neurodegenerative, orthopedic, and other ageing-associated disorders coupled with increasing worldwide geriatric population is driving the market growth. Additionally, increasing prevalence of inheritable genetic diseases is anticipated to fuel the demand in the field of the biotechnology field. However, high treatment costs, operative inefficiency, stringent government regulations, and lack of awareness will restrict the global market for regenerative medicine.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/35229/

The report on global regenerative medicine market covers segments such as type, application and region. Based on application, oncology segment is estimated to witness the fastest XX% CAGR over the forecast period. Many government organizations, as well as private companies, have made high investments in cancer research and development of regenerative & advanced cell therapies. Global efforts to reduce the cancer burden is expected to support the lucrative growth of the oncology segment.North America is the dominating region in the market for regenerative medicine. The major factors promoting regenerative medicine market growth in this region are growing awareness for the use of these medicines to treat various diseases and rising funding line for developing the product line by the private and government organizations.

However, the APAC is considered to grow at a faster rate during the forecast period because of the increasing focus on research and development on regenerative medicine, various government have taken initiative to treat many diseases with the help of regenerative medicines. The report gives a recent development in the market for regenerative medicine like in 2018, Novartis AG received EU approval for one-time gene therapy Luxturna, which has been developed to restore visualization in people with rare and genetically-associated retinal disease. Additionally, in 2017, Integra LifeSciences launched its product, Integra Dermal Regeneration Template Single Layer Thin for dermal repair faults reconstruction in a one-step procedure.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Regenerative Medicine Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTERs analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Global Regenerative Medicine Market.Scope of the Global Regenerative Medicine Market

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/35229/

Global Regenerative Medicine Market, By Type

Cell-Based Immunotherapy & Cell Therapy Productso Allogeneic Productso Autologous Products Tissue-Engineered Products Gene Therapy ProductsGlobal Regenerative Medicine Market, By Application

Musculoskeletal Disorders Wound Care Oncology Ocular Disorders Diabetes OtherGlobal Regenerative Medicine Market, By Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey Players operating in the Global Regenerative Medicine Market

Integra LifeSciences Corporation Astellas Pharma Inc. Ocata Therapeutics, Inc. Corline Biomedical AB Cook Biotech, Inc. Bayer BV BlueRock Therapeutics AstraZeneca MedImmune F. Hoffmann-La Roche Ltd Pfizer Inc. Merck & Co., Inc. Sigma-Aldrich Co. LLC Abbott St. Jude Medical, Inc. Vericel Corporation Novartis AG Alcon GlaxoSmithKline plc. Baxter. Synovis Micro Companies Alliance Inc Amgen Inc. Eli Lilly and Company Bristol-Myers Squibb Company iPierian, Inc Nuvasive, Inc. Organogenesis, Inc. NuTech MiMedx Group, Inc. Stability, LLC. Takara Bio Inc. Caladrius Biosciences, Inc. U.S. Stem Cell, Inc. Cesca Therapeutics Osiris Therapeutics, Inc

MAJOR TOC OF THE REPORT

Chapter One: Regenerative Medicine Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Regenerative Medicine Market Competition, by Players

Chapter Four: Global Regenerative Medicine Market Size by Regions

Chapter Five: North America Regenerative Medicine Revenue by Countries

Chapter Six: Europe Regenerative Medicine Revenue by Countries

Chapter Seven: Asia-Pacific Regenerative Medicine Revenue by Countries

Chapter Eight: South America Regenerative Medicine Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Regenerative Medicine by Countries

Chapter Ten: Global Regenerative Medicine Market Segment by Type

Chapter Eleven: Global Regenerative Medicine Market Segment by Application

Chapter Twelve: Global Regenerative Medicine Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Regenerative Medicine Market Report at:https://www.maximizemarketresearch.com/market-report/global-regenerative-medicine-market/35229/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Original post:
Global Regenerative Medicine Market : Industry Analysis and Forecast (2019-2026): By Type, Application and Region. - Publicist360

Read More...

Hot Stock in the Spotlight:: China Regenerative Medicine International Limited (HKSE:8158) – Investor Welcome

Thursday, April 16th, 2020

China Regenerative Medicine International Limited (HKSE:8158) STOCK IN FOCUS:

Overbought and Oversold levels

The stock has RSI reading of 53.08. RSI gives an indication of the impending reversals or reaction in price of a security. RSI moves in the range of 0 and 100. So an RSI of 0 means that the stock price has fallen in all of the 14 trading days. Similarly, an RSI of 100 means that the stock price has risen in all of the 14 trading days. In technical analysis, an RSI of above 70 is considered an overbought area while an RSI of less than 30 is considered as an oversold area. RSI can be used as a leading indicator as it normally tops and bottoms ahead of the market, thereby indicating an imminent correction in the price of a security. It is pertinent to note that the levels of 70 and 30 needs to be adjusted according to the inherent volatility of the security in question.

If you are considering getting into the day trading or stock market, its a legitimate and profitable method for making a living. Every good investor knows that in order to make money on any investment, you must first understand all aspects of it, so lets look at daily change, stock price movement in some particular time frame, volatility update, performance indicators and technical analysis and analyst rating. Picking a stock is very difficult job. There are many factors to consider before choosing a right stock to invest in it. If picking stock was easy, everyone would be rich right? This piece of financial article provides a short snap of China Regenerative Medicine International Limited regarding latest trading session and presents some other indicators that can help you to support yours research about China Regenerative Medicine International Limited.

China Regenerative Medicine International Limited (HKSE:8158) stock Trading Summary:

China Regenerative Medicine International Limited (HKSE:8158) stock changed position at +1.92%% to closing price of HKD$0.265 in recent trading session. The last closing price represents the price at which the last trade occurred. The last price is also the price on which most charts are based; the chart updates with each change of the last price. The stock registered Last trading volume of 426750 shares. Daily volume is the number of shares that are traded during one trading day. High volume is an indication that a stock is actively traded, and low volume is an indication that a stock is less actively traded. Some stocks tend always to have high volume, as they are popular among day traders and investors alike. Other stocks tend always to have low volume, and arent of particular interest to short-term traders. The stock average trading capacity stands with 1.648M shares and relative volume is now at 0.26 .

China Regenerative Medicine International Limited (HKSE:8158) Stock Price Movement in past 50 Days period and 52-Week period

China Regenerative Medicine International Limited stock demonstrated 12-month low at HKD$0-39.62% and unveiled a 12-month high of HKD$1+239.62%. Prices of commodities, securities and stocks fluctuate frequently, recording highest and lowest figures at different points of time in the market. A figure recorded as the highest/lowest price of the security, bond or stock over the period of past 52 weeks is generally referred to as its 52-week high/ low. It is an important parameter for investors (as they compare the current trading price of the stocks and bonds to the highest/lowest prices they have reached in the past 52 weeks) in making investment decisions. It also plays an important role in determination of the predicted future prices of the stock.

China Regenerative Medicine International Limited (HKSE:8158) Stock Past Performance

China Regenerative Medicine International Limited stock revealed 0.06% return for the recent month and disclosed 0.1522% return in 3-month period. The stock grabbed -0.9732% return over five years and -0.47% return in yearly time period. Past performance shows you the funds track record, but do remember that past performance is not an indication of future performance. Read the historical performance of the stock critically and make sure to take into account both long- and short-term performance. Past performance is just one piece of the puzzle when evaluating investments. Understanding how performance fits in with your overall investing strategy and what else should be considered can keep you from developing tunnel vision.

Volatility in Focus:

The stock unfolded Volatility or average true range percent (ATRP 14) at 0.0507%. Volatility is a rate at which the price of a security increases or decreases for a given set of returns. Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks wont necessarily have lower ATR values than higher priced stocks.

Beta factor is now at 0.86. BETA indicates whether a stock is more or less volatile than the market as a whole. A stock that has a beta score higher than 1 means that volatility is high, while less than 1 means that volatility is low.

Read the original post:
Hot Stock in the Spotlight:: China Regenerative Medicine International Limited (HKSE:8158) - Investor Welcome

Read More...

COLUMN Worried about your immune system? Try these 5 natural remedies – Body aches fever chills and nasal congestion common symptoms of the flu can…

Thursday, April 16th, 2020

San Diego Community News Group

Complications arising from these illnesses can become serious, says Dr. Suhyun An (drsuhyunan.com), an expert on regenerative medicine and co-author of Demystifying Stem Cells: A Real-Life Approach To Regenerative Medicine.

An says there are ways to prevent the symptoms from reaching that serious point. To feel better and get back on your feet, she recommends numerous natural cold and flu remedies to alleviate your symptoms:

Vitamin C. Some studies indicate that vitamin C can shorten the lifespan of a cold and boost your immune system. The best way to get it is through your diet; the fresher the food, the better, An says. Oranges, limes, lemons, grapefruits, leafy greens, and bell peppers are all good sources of vitamin C. Be careful with supplements because they can lead to upset stomach and kidney stones.

Honey. Honey has natural antiviral and antimicrobial properties. Drinking honey in tea with lemon can ease sore throat pain, An says. Research suggests that honey is an effective cough suppressant, too. Honey often contains Clostridium bacteria, so never give honey to a child younger than 1-year-old because infants immune systems arent able to fight them off.

Chicken soup. This popular cold and flu remedy helps because hot liquids reduce mucus buildup and keep you hydrated. Chicken soup, in particular, has anti-inflammatory properties, which help reduce a colds unpleasant side effects, An says. Keep some in the freezer or even canned for flu season. Its quick to prepare that way and soothing to eat.

Aromas. When you have congestion from the flu, applying camphor or menthol salve around your nose can help break up mucus, An says. Aromatherapy oils, such as peppermint and eucalyptus, can have a similar effect. Also, vapor rub can reduce cold symptoms, especially in children older than 2 years. It helps open air passages to combat congestion, reduce coughing, and improve sleep. Its a good alternative to over-the-counter cold medicines in young children because of unwanted side effects.

Probiotics. These are friendly bacteria and yeast found in the body, some foods, and supplements. They can help keep your gut and immune system healthy, and they may reduce your chance of getting sick with an upper respiratory infection, An says. For a delicious and nutritious source of helpful bacteria, include probiotic yogurt in your diet.

Colds and the flu are threats to us every year, but they dont have to get us down for long, An says. Natural home remedies can reduce symptoms so you can be more comfortable and get the rest you need to get better faster.

Dr. Suhyun An is the clinic director at Campbell Medical Group in Houston and an expert on regenerative medicine.

See the original post:
COLUMN Worried about your immune system? Try these 5 natural remedies - Body aches fever chills and nasal congestion common symptoms of the flu can...

Read More...

Global Cartilage Repair and Regeneration Market, by Treatment Modalities, Procedure Type and Application to 2022 – Yahoo Finance

Wednesday, April 1st, 2020

Dublin, April 01, 2020 (GLOBE NEWSWIRE) -- The "Global Cartilage Repair and Regeneration Market, by Treatment Modalities (Cell-Based Approach, Non-Cell-Based Approach), by Procedure Type, by Application, Outlook 2022" report has been added to ResearchAndMarkets.com's offering.

Due to changing lifestyle, a number of disorders like obesity and degenerative joint diseases are affecting the masses across the globe. These factors directly or indirectly develop cartilage injuries; and lead to a decline in the productivity of the working population, which ultimately causes some degree of disability. Therefore, increasing epidemiology of such diseases requires effective treatment options, generating significant demand for regenerative medicine used to restore damaged cartilage.

According to this new release, Global Cartilage Repair and Regeneration Market, by Treatment Modalities (Cell-Based Approach, Non-Cell-Based Approach), by Procedure Type, by Application Outlook 2022 , the industry is expanding at a fast pace. As per this report, the Cartilage Repair and Regeneration market are anticipated to witness high double-digit growth during the forecasted period (2016-2022). This report provides a detailed analysis of the current and future market scenario of the global Cartilage Repair and Regeneration market. The report provides insight into the major factors affecting growth, latest innovations, market segmentation, and competitive landscape.

The report segments the market on the basis of the treatment modalities, procedure type, applications, and geography, with the future forecasts on all prominent segments of the industry till 2022.

Based on treatment modality, the cell-based approaches segment accounts for the largest market share in the overall cartilage repair and regeneration market, due to long-term results of these therapies.

In terms of procedure type, microfracture and ACI are the most common procedure observed amongst all the types of the cartilage repair procedure. Furthermore, in terms of application, the hyaline cartilage repair and regeneration market accounts for the largest share in 2016. It is also expected to be the fastest-growing application segment in the cartilage repair and regeneration market. The large share and high growth of this segment can be attributed to the high prevalence of cartilage damage in hyaline cartilage.

Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America holds the major share in the market. However, the Asia-Pacific region is slated to witness the highest growth in the forecasted period. The growth of the Asia-Pacific market is driven by improving healthcare facilities, raising awareness, increasing prevalence of rheumatoid and osteoarthritis, and increasing government initiatives in this region.

The report finally covers the competitive analysis of the key market players, in terms of their market share and their product offerings. The key vendors dominating the market space are Stryker Corp., Zimmer Biomet Holdings Inc., Smith & Nephew Plc, DePuy Synthes, Inc., etc. The competitive analysis is done at each player level, including their recent developments. To provide a thorough understanding of each player's business model, the player's current and historical financials have been analyzed. Thus, the report provides a comprehensive analysis of cartilage repair & regeneration technology, which will enable investors to design suitable business strategies to target this market.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Cartilage Repair-Overview

4. Market Dynamics4.1 Drivers4.1.1 Growing Incidences of Chondrodystrophies leading to Cartilage Injuries4.1.2 Rising Incidences of Orthopedic Diseases4.1.3 Surge in Sports Injuries4.1.4 Growing Geriatric Popuation4.1.5 Rising Prevalence of Obesity4.1.6 Technological Advancements4.2 Challenges4.2.1 Limited Health Insurance Coverage in Developing Countries4.2.2 High Cost of Knee Cartilage Repair Surgeries4.2.3 Complexity of Cartilage Repair Surgeries4.3 Opportunities4.3.1 Significant US Market Opportunity Due to Unsatisfactory First Line Therapies4.3.2 Emerging Economies to Offer Sustained Growth Opportunities4.3.3 Increased R&D Spending for Advancements in Knee Cartilage Repair4.3.4 Use of Bioactive Growth Factors4.3.5 3D Printing

5. Global Cartilage Repair and Regeneration Market Outlook 2022

6. Cartilage Repair and Regeneration Market, By Treatment Modalities6.1 Cell-Based Approach6.2 Non-Cell-Based Approach

7. Global Cartilage Repair and Regeneration Market, By Procedure Type7.1 Autologous Chondrocyte Transplantation7.2 Cell-Based Cartilage Resurfacing7.3 Microfracture7.4 Osteochondral Allograft7.5 Others

8. Global Cartilage Repair and Regeneration Market, By Application8.1 Hyaline Cartilage Repair and Regeneration8.2 Elastic Cartilage Repair and Regeneration8.3 Fibrous Cartilage Repair and Regeneration

9. Global Cartilage Repair and Regeneration Market, By Geography9.1 North America9.2 Europe9.3 Asia-Pacific

10. Regulatory Landscape

11. Trends & Developments11.1 Cost-Effectiveness Promoting Interest in One-Step Surgery11.2 Bioactive Signals that Enhance Cartilage Repair11.3 Gene Therapy for Cartilage Repair11.4 Mesenchymal Stem Cells

12. Competitive Landscape12.1 Market Share of Key Players12.2 Comparative Analysis of Products

13. Key Players Analysis13.1 Stryker Corporation13.2 B. Braun Melsungen AG13.3 Zimmer Biomet Holdings, Inc.13.4 Smith & Nephew plc13.5 DePuy Synthes, Inc. (A Subsidiary of Johnson & Johnson)13.6 Arthrex, Inc.13.7 Osiris Therapeutics, Inc.13.8 Vericel Corporation13.9 RTI Surgical, Inc.13.10 CONMED Corporation13.11 Anika Therapeutics, Inc.

14. The Future of Cartilage Repair

Story continues

For more information about this report visit https://www.researchandmarkets.com/r/sd7qmv

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read the rest here:
Global Cartilage Repair and Regeneration Market, by Treatment Modalities, Procedure Type and Application to 2022 - Yahoo Finance

Read More...

LETTERS TO THE EDITOR | Opinion – Moscow-Pullman Daily News

Wednesday, April 1st, 2020

I want to add to the praise for the healthcare workers and first responders who are literally our front line in fighting this war we are in against a virus called COVID-19. As a retired medical technologist, I know that drive to do all we can to save the lives of others and not stopping for breaks or meals or even sleep until the work is done. I, thank God, was never in a battle that went on for days and weeks and now months, nor one where my life was at risk everyday when I went to work. Each and every one of you is a hero beyond compare.

In this same war, I am thinking we have not expressed enough praise for another group of frontline workers: those who are working in our grocery stores, hardware stores, drug stores and restaurants to keep us supplied with the essentials we need through this crisis. You are also at higher risk of being exposed than those of us who get to stay home. In positions that have been taken for granted by so many of us in our busy lives, we can now see you for the hugely important role you have always played in keeping society moving smoothly. Thank you.

Support for the most vulnerable

I am writing you to urge the support of legislation that addresses the needs of the most vulnerable:

1) $60 billion for the charitable sector and the construction of a mechanism for a rapid infusion of cash to those organizations serving immediate needs in communities while facing lost and declining revenue due to the pandemic.

2) Create a universal charitable deduction and allow post-March 1, 2020, donations to be claimed on 2019 taxes and future tax returns.

3) Clarify that charitable nonprofits of all sizes are able to participate in the emergency small business loan program by using the tax-law definition of charitable organizations (Sec. 501(c)(3) public charities).

4) Remove the cap on the number of employees and the language excluding nonprofits from receiving Medicaid reimbursements.

5) Increase funding for the Emergency Food and Shelter Program from the existing FY 2020 $125 million to $250 million to help people experiencing dire poverty.

6) Temporarily increase the maximum SNAP benefit.

7) Increase funding to prevent further homelessness. Provide an additional $15 billion for McKinney-Vento Emergency Solutions Grants and $5 billion for short-term rental assistance, like the Disaster Housing Assistance Program.

Thank you for acting in the welfare of the most vulnerable. Our society can only be as strong as our weakest links.

Making a false supposition

In Kenneth Gordons March 26 letter, (Facts vs. Hysteria), he maintained a false supposition: that COVID-19 is a form of flu. COVID-19 is not a form of flu, it is more akin to another coronavirus, the very deadly SARS (Severe Acute Respiratory Syndrome).

COVID-19 is a novel coronavirus, which is an infectious respiratory illness as is influenza; but this is a brand new virus. That means unlike the flu, which has a vaccine and several pharmaceutical therapies (including oseltamivir phosphate or Tamiflu), there are no vaccines or medicines available to treat the illness yet. Clinical trials for effective treatments and vaccines takes time. Another major concern is because COVID-19 is so new, scientists and medical researchers do not yet know if there are any long-term medical implications with this new virus or how frequently it mutates.

What the medical community does know is this new virus kills at a higher rate than influenza. Currently, the Journal of the American Medical Association estimates the virus is killing at a rate of 2.7 percent compared to a death rate of 1 percent for influenza, although the death rate in Italy is 7.2 percent. The World Health Organization is currently saying little slows this bug down, except for being well informed: Social distancing, sneezing/coughing into elbows and people being vigilant in not touching their face plus hand washing, and paying attention to any symptoms.

So, rather than worry about going back to work, instead consider your fellow humans while you may only show few or no symptoms, that germ you pass on may kill another person. Is going back to work fast really worth that risk?

Knowing it is all for the best

I am always thinking of ways to keep in touch with old friends and family from afar, so I am using this letter to the editor to more widely let known I am fine and am not affected yet by COVID 19.

Because of my interest in history, I have been thinking about other pandemics such as typhoid fever and polio and am encouraged by the fact that these diseases are no longer a threat. My grandfather, I believe, contracted typhoid fever from drinking contaminated water in the Wisconsin Dells.

And I remember how relieved I was during the polio epidemic to finally be able to take polio vaccine. We have come a long way with penicillin other miracle drugs, and I want to put in a plug for the advances in regenerative medicine now on the horizon, specifically stem cell therapy that I underwent this past year. One of the advantages of that is that it only took a half day and I could avoid a prolonged hospital stay. With the fear of contamination and spread of viruses, that was significant for me. I miss seeing you all but know it is for the best.

Drinking poison wastheir own mistake

Propylene glycol is used in many processed foods. Ethylene glycol is the main ingredient in antifreeze. They have similar names, but you wouldnt want to drink antifreeze. That would be stupid. Im sure that Charlie Powell (Tooth & Nail, Daily News), who I believe has a personal acquaintance with veterinarians at WSU, has seen what happens to dogs that dip their tongues in antifreeze.

Recently, we learned of an unfortunate couple of people who tried to self-medicate by drinking poison. The poison has a name similar to a common drug that could be an effective treatment for COVID-19. That is very sad, but obviously it was less than wise.

The drug in question has been safely used for decades to treat a variety of ailments, and doctors around the world have seen promising results against the new coronavirus. Mr. Powell, in his March 28 column, notes that there is an elected official who has mentioned this hopeful development, and then clearly suggests that the elected official is responsible for the actions of those unfortunately mistaken people. Negative, Mr. Powell!

People need to be aware of what they are doing, and if they purposely drink poison, its their own mistake. Theirs alone. Sad, but true.

See the original post here:
LETTERS TO THE EDITOR | Opinion - Moscow-Pullman Daily News

Read More...

Avectas partners with Vycellix to speed cell therapy production – BioPharma-Reporter.com

Wednesday, April 1st, 2020

Avectas will provide access to its Solupure platform, which Vycellix will use to deliver its product candidate, VY-M, to T cells and NK cells.

According to Vycellixs president, Douglas Calder, the use of Solupure will allow for the accelerated expansion time of T cells and NK cells by decreasing the non-dividing lag times the overall aim being to reduce the vein-to-vein delivery time to patients.

In addition, the companies hope to reduce the cost of manufacture and to develop proprietary approaches for cell-based immunotherapeutic products.

Both companies are partners within NextGenNK, a center based on the development of NK cell-based cancer immunotherapies in Stockholm, Sweden.

The collaborative studies that will occur between the two partners will be divided between the Karolinska Institutet and Avectas Dublin, Ireland facility.

Vycellix willl use this platform to aid in the development of its pipeline of therapies, which includes VY-101 a retargeted optimized NK cell therapy. The company hopes to be able to submit an investigational new drug filing in 2021 for the treatment candidate.

Avectas recently signed an agreement to also utilize the platform alongside the Centre for Commercialization of Regenerative Medicine to speed up the cell engineering process.

The companys Solupure platform uses membrane disruption to deliver nucleic acids and proteins to cells rather than viral cell engineering.

Read more:
Avectas partners with Vycellix to speed cell therapy production - BioPharma-Reporter.com

Read More...

Allergan Earns ENERGY STAR Partner of the Year – Sustained Excellence Award for the Seventh Consecutive Year – Yahoo Finance

Wednesday, April 1st, 2020

DUBLIN, March 31, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it has received the ENERGY STAR Partner of the Year Sustained Excellence Award for 2020, marking the seventh consecutive year it has earned ENERGY STAR'shighest honor. The U.S. Environmental Protection Agency award recognizes Allergan for its continued leadership in energy management and efficiency.

"Allergan is proud of its longstanding commitment to increasing our energy efficiency and reducing our impact on the environment. Four years ago, we set an aggressive goal to reduce our total energy usage by 20 percent between 2015 and 2020 and today we are well on our way to achieving that goal. We congratulate our global colleagues for their tremendous efforts to support environmental responsibility, which continue to be recognized year after year," saidWayne Swanton, Executive Vice President, Global Operations atAllergan.

Prior to earning the ENERGY STAR Sustained Excellence distinction for the last seven years, Allergan was recognized as an ENERGY STAR Partner of the Year for two consecutive years. Additionally, Allergan's manufacturing facility in Waco, Texas was recently named an ENERGY STAR Certified Manufacturing Plant for superior energy performance, a distinction earned only by plants in the top 25 percent of energy performance in the United States. Allergan also achieved ENERGY STAR certification for a building located at its Irvine, California campus.Allerganhas been an ENERGY STARpartner since 1996.

For a complete list of 2020 winners and more information about ENERGY STAR's awards program, visit energystar.gov/awardwinners.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website atwww.Allergan.com.

About ENERGY STAR

ENERGY STARis the government-backed symbol for energy efficiency, providing simple, credible, and unbiased information that consumers and businesses rely on to make well-informed decisions. Thousands of industrial, commercial, utility, state, and local organizationsincluding more than 40 percent of the Fortune 500 companiesrely on their partnership with EPA to deliver cost-saving energy efficiency solutions. Since 1992, ENERGY STAR and its thousands of partners helped American families and businesses save more than 4 trillion kilowatt-hours of electricity and achieve over 3.5 billion metric tons of greenhouse gas reductions. In 2018 alone, ENERGY STAR and its partners helped Americans avoid nearly $35 billion in energy costs. More background information about ENERGY STAR can be found at: energystar.gov/about and energystar.gov/numbers.

Story continues

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences;difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2019. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:

Allergan: Investors:Manisha Narasimhan, PhD(862) 261-7488

Media:Lisa Brown(862) 261-7320

View original content to download multimedia:http://www.prnewswire.com/news-releases/allergan-earns-energy-star-partner-of-the-year--sustained-excellence-award-for-the-seventh-consecutive-year-301032547.html

SOURCE Allergan plc

Continue reading here:
Allergan Earns ENERGY STAR Partner of the Year - Sustained Excellence Award for the Seventh Consecutive Year - Yahoo Finance

Read More...

Here are the departments accepting S/NC in spring 2020 – The Stanford Daily

Wednesday, April 1st, 2020

On Thursday, the Faculty Senate voted 36-15 to mandate that all spring quarter courses be graded on a satisfactory/no-credit (S/NC) basis. Courses in the Stanford Graduate School of Business, Stanford Law School and Stanford School of Medicines M.D. program were exempt from this decision, but those schools may opt in.

The Senate also approved a measure that strongly urges departments and programs to exclude units of credit earned for a CR or S grade during spring quarter 2019-20 from program unit maximums and/or alter program requirements as appropriate.

The Daily has reached out to all of Stanfords departments, schools and programs that offer undergraduate and/or graduate degrees to compile a list of those accepting courses taken on a S/NC basis this spring for degree requirements. Ways of Thinking/Ways of Doing, Thinking Matters and Program in Writing and Rhetoric courses taken S/NC in the spring will also count toward undergraduate graduation requirements.

No departments, schools or programs have yet said that they will not be accepting courses taken S/NC this spring. The following list will be updated as The Daily receives additional responses.

Graduate School of EducationEducation (Minor)

School of Earth, Energy & Environmental Sciences (All degrees)

School of EngineeringAeronautics and Astronautics (Major, Minor)Architectural Design (Major)Atmosphere and Energy (Major)Bioengineering (All degrees)Biomechanical Engineering (Major)Biomedical Computation (Major)Chemical Engineering (Major, Minor)Civil Engineering (Major, Minor)Computer Science (Major, Minor, M.S.)Electrical Engineering (Major, Minor)Engineering Physics (Major)Environmental Systems Engineering (Major, Minor)Management Science and Engineering (Major, Minor)Materials Science and Engineering (Major, Minor)Mechanical Engineering (All degrees)Product Design (Major)

School of Humanities & SciencesAmerican Studies (Major, Minor)Applied Physics (All degrees)Archaeology (Major, Minor)Biology (Major, Minor)Center for Comparative Studies in Race & Ethnicity (Major, Minor)Chemistry (Major, Minor)Classics (Major, Minor)Communication (All degrees)Creative Writing (Minor)Data Science (Minor)Division of Literatures, Cultures, and Languages (All degrees)Economics (Major, Minor)English (Major, Minor)Human Biology (Major, Minor)Human Rights (Minor)International Relations (Major, Minor)Linguistics (Major, Minor)Mathematical and Computational Science (Major, Minor)Mathematics (Major, Minor)Music (Major, Minor)Philosophy (Major, Minor)Physics (Major, Minor)Political Science (Major, Minor)Psychology (Major, Minor)Public Policy (Major, Minor)Religious Studies (Major, Minor)Sociology (Major, Minor)Statistics (Minor)Symbolic Systems (Major, Minor)Urban Studies (Major, Minor)

School of MedicineBiochemistry (All degrees)Bioengineering (All degrees)Biomedical Informatics (All degrees)Biophysics (All degrees)Cancer Biology (All degrees)Chemical and Systems Biology (All degrees)Epidemiology & Clinical Research (M.S., Ph.D.)Genetics (All degrees)Health Policy (M.S., Ph.D.)Immunology (All degrees)Microbiology and Immunology (All degrees)Neurosciences (All degrees)Stem Cell Biology and Regenerative Medicine (All degrees)

Contact Camryn Pak at cpak23 at stanford.edu.

See the original post here:
Here are the departments accepting S/NC in spring 2020 - The Stanford Daily

Read More...

Coronavirus: BU Wednesday Roundup | BU Today – BU Today

Wednesday, April 1st, 2020

If you have a question or comment related to BU and its response to the COVID-19 crisis, on the subject of the move-out, remote learning, retrieving personal belongings, or anything else, please visit Boston Universitys special COVID-19 website. Questions are being answered there by specific departments in a timely fashion. Thank you. Doug Most, executive editor, BU Today

Even the dogs wont come downstairs.

Number killed in the 9/11 attacks:

2,977

BU-based Boston Playwrights Theatre (BPT) will present a very different Boston Theater Marathon when the annual event begins today, Wednesday, April 1, and it might be just the distraction that all us shut-ins need.

More than 200 Boston-area theater artists are working on Boston Theater Marathon XXII: Special Zoom Edition, which features 10-minute plays written by New England playwrights and presented by New England theater companies. There will be one broadcast every day at noon for more than a month on Zoom, the videoconferencing tool that just about everyone is using to stay in touch these days. Find a complete schedule, with Zoom links, here.

The Elliot Norton Awardwinning marathon, a yearly community-based charity event benefiting the Theatre Community Benevolent Fund, was scheduled for April 19, but was canceled as the coronavirus pandemic escalated earlier this month. Audiences who dial in to the event will be encouraged to donate to participating theater companies and/or to the Theatre Community Benevolent Fund.

We wont let this necessary distancing stop these gifted playwrights and these wonderful companies from coming together to celebrate new work, says BPT and Marathon artistic director Kate Snodgrass (GRS90), a College of Arts & Sciences professor of the practice of playwriting. Theater will continuewhether its on the stage or in our hearts (or rather, in this case, on Zoom). Whether its for 10 minutes or for 10 hours, art lives.

This years Theater Marathon was intended to be a homecoming of sortsthe first time the event had been held at Boston Playwrights Theatre since 2004. (It was at the Huntington Theatre Companys Virginia Wimberly Theatre at the Boston Center for the Arts from 2005 to 2019.) Instead of honoring our past, times dictate that we try something new, says K. Alexa Mavromatis (GRS11), BPT marketing director.

Todays first installment is Three Ladybugs, by Vicki Meagher, sponsored by Boston Playwrights Theatreand featuring an all-BU cast. Its directed by Darren Evans (CAS95), stars Melinda Lopez (GRS00), a CAS adjunct assistant professor of playwriting, as Atheist Ladybug, and veteran Boston stage actors Paula Plum (CFA75) as Agnostic Ladybug and Karen McDonald (CFA72) as Believer Ladybug. Snodgrass and Evans have voice-over parts (Woman and Man) and Mavromatis will read stage directions. Playwrights represented this year include Mavromatis and Ronn Noone (GRS01), as well as local stalwarts like Patrick Gabridge and John Kuntz (GRS05).

The Theater Marathon is traditionally presented as a 10-hour, all-day affair featuring 10-minute plays by 50 New England playwrights and produced by 50 New England theater companies. Instead, this year it will be a daily Zoom-based lunch break through May 17. Readings will begin each day at noon and last approximately 15 minutes. Audiences will need to download the free Zoom app to participate, and it is recommended that they call in a few minutes before curtain time. Nearly every playwright and theater company tapped to participate in the onstage version will be part of the Zoom event.

And yes, the Zoom events will be set up so only the performers are seen and heard.

On Thursday, April 2, all BU alumni, students, faculty, and staff across the globe are asked to wear BU gear for the day and post proudly across social channels using #TerriersTogetheralong with messages of positivity and connection for the BU community. The #TerriersTogether web page asks students and alums to:

The page also offers downloadable Zoom backgrounds so at your next meeting you can make it look like youre at the BU Beach or the GSU.

A couple of BU Today stories we want to be sure you didnt miss: 50 Boston collaborators gathered at the Center for Regenerative Medicine (CReM) on Boston Universitys Medical Campus in March to develop their own FDA-approved coronavirus test. A Questrom supply-chain expert says stock up, yes, but dont panic about food supplies. Also: Former Patriots tight end Rob Gronkowski and model Camille Kostek have donated 10,000 medical-grade KN95 masks to both Boston Medical Center and St. Josephs University Medical Center in New Jersey, in an effort to assist with the high demand for personal protective equipment (PPE) during the pandemic. And finally, if you have followed the conventional wisdom as it evolves toward everybody wear a mask when you go outside, heres how to make your own.

The Massachusetts governor announced Tuesday that he is extending the order closing nonessential businesses and that the state Department of Public Health will keep its stay-at-home advisory in place, both until May 4, matching planned school closures. Gatherings larger than 10 people are also banned. The White House on Sunday extended guidelines for Americans to maintain social distancing through April 30.

An updated list of essential businesses is being distributed. Among the changes: hotels, motels, and short-term rentals like AirBnBs can no longer be booked for leisure purposes. They may be used only for efforts related to fighting COVID-19, like frontline health workers, or for Massachusetts residents who have been otherwise displaced from their residences. People should really be using common sense and not going on vacation right now, Baker said.

The FBI has received multiple reports of conferences being disrupted by pornographic and/or hate images and threatening language, the Boston Globe reports. Apparently, now that were all using Zoom to study and stay connected in an age of social distancing, it has become fertile ground for trolls and hate-mongers. The feds recommend that you use passwords and other Zoom features to prevent disrupters from getting into your work meetings and virtual cocktail parties.

The White House released the epidemiological models of the spread of coronavirus in the United States that painted such a grim picture that President Trump gave up his plan to reopen the country on Easter. Trump warned Americans of a very, very painful two weeks ahead. The models showed the virus is likely to kill 100,000 to as many as 240,000Americans this year. Trump now says social distancing and business closures will continue through April.

A nationwide trial is underway to see if the drug hydroxychloroquine can prevent disease in people exposed to the novel coronavirus. A second trial will test to see if the drug can prevent severe disease in people who are already showing COVID-19 symptoms. Both are run by a University of Minnesota infectious disease specialist.

United States, 174,467; Massachusetts, 6,620.

FindBU Todays latest coverage of the pandemichere. The Universitys hotline for faculty, staff, students, and visiting scholars to call for referral of their virus-related medical concerns is 617-358-4990.

Read the original post:
Coronavirus: BU Wednesday Roundup | BU Today - BU Today

Read More...

2020 Canada Gairdner Awards Recognize World-renowned Scientists for Transformative Contributions to Research That Impact Human Health – Benzinga

Wednesday, April 1st, 2020

TORONTO, March 31, 2020 /CNW/ - The Gairdner Foundation is pleased to announce the 2020 Canada Gairdner Award laureates, recognizing some of the world's most significant biomedical research and discoveries. During these challenging times, we believe it is important to celebrate scientists and innovators from around the world and commend them for their tireless efforts to conduct research that impacts human health.

2020 Canada Gairdner International AwardThe five 2020 Canada Gairdner International Award laureates are recognized for seminal discoveries or contributions to biomedical science:

Dr. Masatoshi TakeichiSenior Visiting Scientist, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan; Professor Emeritus, Kyoto University, Kyoto, Japan

Dr. Rolf KemlerEmeritus Member and Director, Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany

Awarded "For their discovery, characterization and biology of cadherins and associated proteins in animal cell adhesion and signalling."

Dr. Takeichi

The Work: The animal body is made up of numerous cells. Dr. Takeichi was investigatinghow animal cells stick together to form tissues and organs, and identified a key protein which he named 'cadherin'.Cadherin is present on the surface of a cell and binds to the same cadherin protein on the surface of another cell through like-like interaction, thereby binding the cells together. Without cadherin, cell to cell adhesion becomes weakened and leads to the disorganization of tissues. Dr. Takeichi found that there are multiple kinds of cadherin within the body, each of which are made by different cell types, such as epithelial and neuronal cells. Cells with the same cadherins tend to cluster together, explaining the mechanism of how different cells are sorted out and organized to form functional organs.

Further studies by Dr. Takeichi's group showed that cadherin function is supported by a number of cytoplasmic proteins, includingcatenins, and their cooperation is essential for shaping of tissues. His studies also revealed that the cadherin-dependent adhesion mechanism is involved in synaptic connections between neurons, which are important for brain wiring.

Dr. Kemler

The Work: Dr. Kemler, using an immunological approach, developed antibodies directed against surface antigens of early mouse embryos. These antibodies were shown to prevent compaction of the mouse embryo and interfered with subsequent development. Both Dr. Kemler and Dr. Takeichi went on to clone and sequence the gene encoding E-cadherin and demonstrate that it was governing homophilic cell adhesion.

Dr. Kemler also discovered the other proteins that interact with the cadherins, especially the catenins, to generate the machinery involved in animal cell-to-cell adhesion. This provided the first evidence of their importance in normal development and diseases such as cancer. It has been discovered that cadherins and catenins are correlated to the formation and growth of some cancers and how tumors continue to grow. Beta catenin is linked to cell adhesion through interaction with cadherins but is also a key component of the Wnt signalling pathway that is involved in normal development and cancer. There are approximately 100 types of cadherins, known as the cadherin superfamily.

Dr. Takeichi

The Impact: The discovery of cadherins, which are found in all multicellular animalspecies, has allowed us to interpret how multicellular systems are generated and regulated. Loss of cadherin function has been implicated as the cause of certain cancers, as well as in invasiveness of many cancers. Mutations in special types of cadherin result in neurological disorders, such as epilepsy and hearing loss. The knowledge of cadherin function is expected to contribute to the development of effective treatments against such diseases.

Dr. Kemler

The Impact: Human tumors are often of epithelial origin. Given the role of E-cadherin for the integrity of an epithelial cell layer, the protein can be considered as a suppressor of tumor growth. The research on the cadherin superfamily has had great impact on fields as diverse as developmental biology, cell biology, oncology, immunology and neuroscience. Mutations in cadherins/catenins are frequently found in tumors. Various screens are being used to identify small molecules that might restore cell adhesion as a potential cancer therapy.

Dr. Roel NusseProfessor & Chair, Department of Developmental Biology; Member, Institute for StemCell Biology andRegenerativeMedicine, Stanford University, School of Medicine.Virginia and Daniel K. Ludwig Professor of Cancer Research. Investigator, Howard Hughes Medical Institute

Awarded"For pioneering work on the Wnt signaling pathway and its importance in development, cancer and stem cells"

The Work: Dr. Nusse's research has elucidated the mechanism and role of Wnt signaling, one of the most important signaling systems in development. There is now abundant evidence that Wnt signaling is active in cancer and in control of proliferation versus differentiation of adult stem cells, making the Wnt pathway one of the paradigms for the fundamental connections between normal development and cancer.

Among Dr. Nusse's contributions is the original discovery of the first Wnt gene (together with Harold Varmus) as an oncogene in mouse breast cancer. Afterwards Dr. Nusse identified the Drosophila Wnt homolog as a key developmental gene, Wingless. This led to the general realization of the remarkable links between normal development and cancer, now one of the main themes in cancer research. Using Drosophila genetics, he established the function of beta-catenin as a mediator of Wnt signaling and the Frizzleds as Wnt receptors (with Jeremy Nathans), thereby establishing core elements of what is now called the Wnt pathway. A major later accomplishment of his group was the first successful purification of active Wnt proteins, showing that they are lipid-modified and act as stem cell growth factors.

The Impact: Wnt signaling is implicated in the growth of human embryos and the maintenance of tissues. Consequently, elucidating the Wnt pathway is leading to deeper insights into degenerative diseases and the development of new therapeutics. The widespread role of Wnt signaling in cancer is significant for the treatment of the disease as well. Isolating active Wnt proteins has led to the use of Wnts by researchers world-wide as stem cell growth factors and the expansion of stem cells into organ-like structures (organoids).

Dr. Mina J. Bissell Distinguished Senior Scientist, Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory; Faculty; Graduate Groups in Comparative Biochemistry, Endocrinology, Molecular Toxicology and Bioengineering, University of California Berkeley, Berkeley, CA, USA

Awarded "For characterizing "Dynamic Reciprocity" and the significant role that extracellular matrix (ECM) signaling and microenvironment play in gene regulation in normal and malignant cells, revolutionizing the fields of oncology and tissue homeostasis."

The Work: Dr. Mina Bissell's career has been driven by challenging established paradigms in cellular and developmental biology. Through her research, Dr. Bissell showed that tissue architecture plays a dominant role in determining cell and tissue phenotype and proposed the model of 'dynamic reciprocity' (DR) between the extracellular matrix (ECM) and chromatin within the cell nucleus. Dynamic reciprocity refers to the ongoing, bidirectional interaction between cells and their microenvironment. She demonstrated that the ECM could regulate gene expression just as gene expression could regulate ECM, and that these two phenomena could occur concurrently in normal or diseased tissue.

She also developed 3D culture systems to study the interaction of the microenvironment and tissue organization and growth, using the mammary gland as a model.

The Impact:Dr. Bissell's model of dynamic reciprocity has been proven and thoroughly established since its proposal three decades ago and the implications have permeated every area of cell and cancer biology, with significant implications for current and future therapies. Dr. Bissell's work has generated a fundamental and translationally crucial paradigm shift in our understanding of both normal and malignant tissues.

Her findings have had profound implications for cancer therapy by demonstrating that tumor cells can be influenced by their environment and are not just the product of their genetic mutations. For example, cells from the mammary glands grown in two-dimensional tissue cultures rapidly lose their identity, but once placed in proper three-dimensional microenvironments, they regain mammary form and function. This work presages the current excitement about generation of 3D tissue organoids and demonstrates Dr. Bissell's creative and innovative approach to science.

Dr. Elaine FuchsHoward Hughes Medical Institute Investigator and Rebecca C. Lancefield Professor and Head of the Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Cell Biology; The Rockefeller University, New York, NY, USA

Awarded"For her studies elucidating the role of tissue stem cells in homeostasis, wound repair, inflammation and cancer."

The Work: Dr. Fuchs has used skin to study how the tissues of our body are able to replace dying cells and repair wounds. The skin must replenish itself constantly to protect against dehydration and harmful microbes. In her research, Fuchs showed that this is accomplished by a resident population of adult stem cells that continually generates a shell of indestructible cells that cover our body surface.

In her early research, Fuchs identified the proteins---keratinsthat produce the iron framework of the skin's building blocks, and showed that mutations in keratins are responsible for a group of blistering diseases in humans. In her later work, Fuchs identified the signals that prompt skin stem cells to make tissue and when to stop. In studying these processes, Fuchs learned that cancers hijack the fundamental mechanisms that tissue stem cells use to repair wounds. Her team pursued this parallel and isolated and characterized the malignant stem cells that are responsible for propagating a type of cancer called "squamous cell carcinoma." In her most recent work, she showed that these cells can be resistant to chemotherapies and immunotherapies and lead to tumor relapse.

The Impact: All tissues of our body must be able to replace dying cells and repair local wounds. Skin is particularly adept at performing these tasks. The identification and characterization of the resident skin stem cells that make and replenish the epidermis, sweat glands and hair provide important insights into this fountain of youth process and hold promise for regenerative medicine and aging. In normal tissues, the self-renewing ability of stem cells to proliferate is held in check by local inhibitory signals coming from the stem cells' neighbours. In injury, stimulatory signals mobilize the stem cells to proliferate and repair the wound. In aging, these normal balancing cues are tipped in favour of quiescence. In inflammatory disorders, stem cells become hyperactivated. In cancers, the wound mechanisms to mobilize stem cells are hijacked, leading to uncontrolled tissue growth. Understanding the basic mechanisms controlling stem cells in their native tissue is providing new strategies for searching out refractory tumor cells in cancer and for restoring normalcy in inflammatory conditions.

2020 John Dirks Canada Gairdner Global Health AwardThe 2020 John Dirks Canada Gairdner Global Health Award laureate is recognized for outstanding achievements in global health research:

Professor Salim S. Abdool KarimDirector of CAPRISA (Centre for the AIDS Program of Research in South Africa), the CAPRISA Professor in Global Health at Columbia University, New York and Pro Vice-Chancellor (Research) at the University of KwaZulu-Natal, Durban, South Africa

Professor Quarraisha Abdool KarimAssociate Scientific Director of CAPRISA, Professor in Clinical Epidemiology, Columbia University, New York and Professor in Public Health at the Nelson Mandela Medical School and Pro Vice-Chancellor (African Health) at the University of KwaZulu-Natal, Durban, South Africa

Awarded"For their discovery that antiretrovirals prevent sexual transmission of HIV, which laid the foundations for pre-exposure prophylaxis (PrEP), the HIV prevention strategy that is contributing to the reduction of HIV infection in Africa and around the world."

The Work: UNAIDS estimates that 37 million people were living with HIV and 1.8 million people acquired HIV in 2017. In Africa, which has over two thirds of all people with HIV, adolescent girls and young women have the highest rates of new HIV infections. ABC (Abstinence, Be faithful, and use Condoms) prevention messages have had little impact - due to gender power imbalances, young women are often unable to successfully negotiate condom use, insist on mutual monogamy, or convince their male partners to have an HIV test.

In responding to this crisis, Salim and Quarraisha Abdool Karim started investigating new HIV prevention technologies for women about 30 years ago. After two unsuccessful decades, their perseverance paid off when they provided proof-of-concept that antiretrovirals prevent sexually acquired HIV infection in women. Their ground-breaking CAPRISA 004 trial showed that tenofovir gel prevents both HIV infection and genital herpes. The finding was ranked inthe "Top 10 Scientific Breakthroughs of 2010" by the journal, Science. The finding was heralded by UNAIDS and the World Health Organization (WHO) as one of the most significant scientific breakthroughs in AIDS and provided the first evidence for what is today known as HIV pre-exposure prophylaxis (PrEP).

The Abdool Karims have also elucidated the evolving nature of the HIV epidemic in Africa, characterising the key social, behavioural and biological risk factors responsible for the disproportionately high HIV burden in young women. Their identification of the "Cycle of HIV Transmission", where teenage girls acquire HIV from men about 10 years older on average, has shaped UNAIDS policies on HIV prevention in Africa.

The impact: CAPRISA 004 and several clinical trials of oral tenofovir led tothe WHO recommending a daily tenofovir-containing pill for PrEP as a standard HIV prevention tool for all those at high risk a few years later. Several African countries are among the 68 countries across all continents that are currently making PrEP available for HIV prevention. The research undertaken in Africa by this South African couple has played a key role in shaping the local and global response to the HIV epidemic.

2020 Canada Gairdner Wightman AwardThe 2020 Canada Gairdner Wightman Award laureate is a Canadian scientist recognized for outstanding leadership in medicine and medical science throughout their career:

Dr. Guy Rouleau Director of the Montreal Neurological Institute-Hospital (The Neuro); Professor & Chair of the Department of Neurology and Neurosurgery, McGill University; Director of the Department of Neuroscience, McGill University Health Center

Awarded "For identifying and elucidating the genetic architecture of neurological and psychiatric diseases, including ALS, autism and schizophrenia, and his leadership in the field of Open Science."

The Work: Dr. Rouleau has identified over 20 genetic risk factors predisposing to a range of brain disorders, both neurological and psychiatric, involving either neurodevelopmental processes or degenerative events. He has defined a novel disease mechanism for diseases related to repeat expansions that are at play in some of the most severe neurodegenerative conditions. He has significantly contributed to the understanding of the role of de novo variants in autism and schizophrenia. In addition, he has made important advances for various neuropathies, in particular for amyotrophic lateral sclerosis (ALS) where he was involved in the identification of the most prevalent genetic risk factors -which in turn are now the core of innumerable ALS studies worldwide.

Dr. Rouleau has also played a pioneering role in the practice of Open Science (OS), transforming the Montreal Neurological Institute-Hospital (The Neuro) into the first OS institution in the world. The Neuro now uses OS principles to transform research and careand accelerate the development of new treatments for patients through Open Access, Open Data, Open Biobanking, Open Early Drug Discovery and non-restrictive intellectual property.

The Impact: The identification of genetic risk factors has a number of significant consequences. First, allowing for more accurate genetic counselling, which reduces the burden of disease to affected individuals, parents and society. A revealing case is Andermann syndrome, a severe neurodevelopmental and neurodegenerative condition that was once relatively common in the Saguenay-Lac-St-Jean region of Quebec. Now this disease has almost disappeared from that population. Second, identifying the causative gene allows the development of treatments. For instance, his earlier work on a form of ALS linked to the superoxide dismutase-1 gene (SOD1) opened up studies which are now the focal point of phase 2 clinical studies showing great promise.

Byactingasalivinglabforthelast coupleofyears,TheNeuroisspearheading the practice of OpenScience (OS).TheNeurois alsoengagingstakeholdersacross Canadawiththegoal of formalizinganational OSallianceforthe neurosciences.Dr.Rouleau'sworkinOScontributesfundamentallytothetransformationoftheveryecosystemofsciencebystimulatingnewthinkingandfosteringcommunitiesofsharing.InspiredbyTheNeuro'svision,theglobalsciencecommunityisreflecting oncurrentresearchconventionsandcollaborativeprojects,andthemomentumforOSisgainingafootholdinorganizationsandinstitutionsinallcornersoftheearth.

About the Gairdner Foundation:

The Gairdner Foundation was established in 1957 by Toronto stockbroker, James Gairdner to award annual prizes to scientists whose discoveries have had major impact on scientific progress and on human health. Since 1959 when the first awards were granted, 387scientists have received a Canada Gairdner Award and 92 to date have gone on to receive the Nobel Prize.The Canada Gairdner Awards promote a stronger culture of research and innovation across the country through our Outreach Programs including lectures and research symposia. The programs bring current and past laureates to a minimum of 15 universities across Canada to speak with faculty, trainees and high school students to inspire the next generation of researchers. Annual research symposia and public lectures are organized across Canada to provide Canadians access to leading science through Gairdner's convening power.

http://www.gairdner.org

SOURCE Gairdner Foundation

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2020/31/c7291.html

Go here to see the original:
2020 Canada Gairdner Awards Recognize World-renowned Scientists for Transformative Contributions to Research That Impact Human Health - Benzinga

Read More...

Renal Insufficiency May Be Associated With Impaired Regenerative Capacity in CAD – The Cardiology Advisor

Wednesday, April 1st, 2020

The following article is part of conference coverage from the American College of Cardiology (ACC.20) /World Congress of Cardiology. The Cardiology Advisors staff is reporting on research conducted by leading experts in cardiology. Check back for the latest news from the ACC.20.

Renal insufficiency may be linked to reduced circulating progenitor cell (CPC) counts, a factor indicative of impaired regenerative capacity in older adults with coronary artery disease (CAD), according to study results intended to be presented at the annual meeting of the American College of Cardiology (ACC 2020).

Anurag Mehta, MBBS, from the Emory University School of Medicine, Atlanta, Georgia, and colleagues estimated the number of CPCs with flow cytometry. CPCs were CD45med+ cells with a single nucleus expressing epitopes for CD34 and CD133. The samples of 1281 patients with CAD (mean age, 66 years; 39% women; 21% black) were analyzed. The association between renal insufficiency (ie, estimated glomerular filtration rate <60 mL/min/1.73 m2) and log-transformed CPC counts was examined using adjusted linear regression models. Furthermore, using adjusted Cox models, the investigators assessed the predictive value of CPC counts for cardiovascular death or myocardial infarction during a 3.5-year median follow-up period.

In unadjusted analyses renal insufficiency wasfound to be associated with lower counts of CD34+ cells (-10.1%; 95%CI, -16.9% to -2.8%; P =.008) and withlower counts of CD34+/CD133+ cells (-11.4%; 95% CI,-19.4% to -2.6%; P =.13) in 446patients.

After adjusting for age, renal insufficiencywas independently associated with lower counts of CD34+ cells (14.5%;95% CI, -24.4% to -3.4%; P =.012) andwith lower counts of CD34+/CD133+ cells (-15.7%; 95% CI,-28.7% to -0.4%; P =.045) in patients70 years. Patients with renal insufficiency who had counts below the medianfor CD34+ or CD34+/CD133+ cells were found tobe at a higher risk for adverse events (adjusted hazard ratio, 1.76; 95% CI,1.24-2.52 and adjusted hazard ratio, 1.80; 95% CI, 1.26-2.56, respectively).Notably, patients with renal insufficiency and CPC counts above the medianvalue had a similar risk for cardiovascular death or myocardial infarctioncompared with patients without renal insufficiency.

The investigators concluded, Impairedregenerative capacity in patients with CAD and [renal insufficiency] independentlypredicts cardiovascular risk.

Reference

Mehta A, Tahhan AS, Liu C, et al. Impaired regenerative capacity predicts outcomes in patients with coronary artery disease and renal insufficiency. Intended to be presented at: American College of Cardiology 69th Annual Scientific Session; March 28-30, 2020; Chicago, IL. Presentation 915-07. Accessed March 24, 2020.

Visit The Cardiology Advisors conference section for coverage intended to be presented at the annual meeting of the American College of Cardiology (ACC.20)/World Congress of Cardiology

See the original post:
Renal Insufficiency May Be Associated With Impaired Regenerative Capacity in CAD - The Cardiology Advisor

Read More...

Clinical Outcomes Of Mesoblast’s Cell Therapy In End-stage Ischemic Heart Failure Presented At American College Of Cardiology Virtual Scientific…

Tuesday, March 31st, 2020

NEW YORK, March 30, 2020 (GLOBE NEWSWIRE) -- Results from a sub-study of 70 patients with end-stage ischemic heart failure and a Left Ventricular Assist Device (LVAD), of 159 randomized patients who received either Mesoblasts allogeneic mesenchymal precursor cell (MPC) product candidate Revascor or saline, were presented on March 28 at the American College of Cardiology (ACC) Virtual Scientific Sessions. The full results from these 70 patients will be published in a peer-reviewed journal.

When compared to controls, in MPC recipients:

The conclusions were:

End-stage ischemic heart failure patients with LVADs are older and have co-morbidities such as diabetes, thereby closely resembling the majority of patients in Mesoblasts 566-patient Phase 3 trial for advanced chronic heart failure, planned to readout in mid-2020.

Revascor is being developed for use in end-stage ischemic heart failure patients with LVADs under existing FDA Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designations.

About Mesoblast Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblasts proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has filed a Biologics License Application to the United States Food and Drug Administration (FDA) to seek approval of its product candidate RYONCIL (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GvHD). Remestemcel-L is also being developed for other rare diseases. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. If approved, RYONCIL is expected to be launched in the United States in 2020 for pediatric steroid-refractory acute GVHD. Two products have been commercialized in Japan and Europe by Mesoblasts licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. This IP position is expected to provide the Company with substantial commercial advantages as it develops its product candidates for these conditions.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see http://www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Forward-Looking Statements This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward- looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward- looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about the timing, progress and results of Mesoblasts preclinical and clinical studies; Mesoblasts ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblasts product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblasts actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For further information, please contact:

See the article here:
Clinical Outcomes Of Mesoblast's Cell Therapy In End-stage Ischemic Heart Failure Presented At American College Of Cardiology Virtual Scientific...

Read More...

Covington-based CTI partners with Humanigen for study of Lenzilumab for treatment of Coronavirus – User-generated content

Tuesday, March 31st, 2020

Covington-based CTIClinical Trial and Consulting Services has partnered with California-based Humanigen, Inc. on a study for the treatment of novel coronavirus 2019 (COVID-19).

Humanigen, Inc., (HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the companys proprietary Humaneered anti-human-granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody, announced that the company has submitted an initial protocol synopsis to the FDA in support of the companys plans to initiate a multi-center, US, Phase III study in COVID-19 patients.

The study, if approved, will be a randomized, controlled, clinical trial with lenzilumab for the prevention of ARDS and/or death in hospitalized patients with pneumonia associated with coronavirus 2 (SARS-CoV-2) infection in COVID-19.

The study will be conducted in partnership with CTI, which specializes in complex programs for critically and chronically ill patients.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms.

Humanigen has pioneered the field of GM-CSF neutralization and, unlike others, has already conducted two Phase I and two Phase II studies, including in patients with severe respiratory conditions, with excellent safety results, said Dr. Cameron Durrant, chief executive officer of Humanigen. We have been working on prevention of cytokine storm for nearly three years. Lenzilumab has an excellent safety and tolerability profile and has not been associated with serious adverse events, including in patients who are immunosuppressed or with severe asthma. Subject to discussion and agreement with regulatory authorities, we intend to progress as quickly as possible with this study.

More details on the companys programs in COVID-19 can be found on the companys websiteunder the COVID-19 tab.

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO).

It delivers a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization.

CTIs focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations.

Schroeder

The COVID-19 pandemic demands an unprecedented response from the pharmaceutical and biotechnology communities, requiring innovation, collaboration, and prioritization of speed without the cost of safety, remarked Tim Schroeder, founder and CEO of CTI. We are proud to have the opportunity to collaborate on such a response with the Humanigen team and to work together to develop an effective treatment solution for those hardest hit by COVID-19.

CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific.

For more information on CTI, click here.

Study to tackle leading cause of death in COVID-19 patients

Lenzilumab, a monoclonal antibody that neutralizes granulocyte macrophage colony stimulating factor (GM-CSF)

GM-CSF is up-regulated in COVID-19 patients and may cause a harmful immune response leading to acute respiratory distress syndrome (ARDS)

Clinical evidence suggests that this harmful immune response contributes to cytokine storm in COVID-19 patients at risk of developing ARDS

Company plans to study lenzilumab in COVID-19 patients to prevent ARDS and mortality with CTI Clinical Trial and Consulting Services (CTI)

COVID-19 is an infectious disease caused by SARS-CoV-2. COVID-19 has become a global pandemic, with over 460,000 confirmed cases and over 21,000 deaths reported to date. Patients with severe cases of COVID-19 experience severe viral pneumonia that can progress to acute respiratory distress syndrome (ARDS) and death.

ARDS is an acute, life-threatening inflammatory lung injury characterized by hypoxia a lack of oxygen to the tissue and stiff lungs due to increased pulmonary vascular permeability. ARDS necessitates hospitalization and mechanical ventilation. A rapid increase in patients with ARDS presents a major challenge for the global public health system given limited hospital beds and ventilators. When implementing standard of care, including mechanical ventilation, ARDS has an overall mortality rate of greater than 40 percent.

Humanigen, Inc. study is focused on the belief that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection as well as the serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thus breaking the efficacy/toxicity linkage.

The companys immediate focus is to prevent or minimize the cytokine storm that precedes severe lung dysfunction and ARDS in cases of pneumonia-associated SARS-CoV-2 infection and also in combining FDA-approved and development stage CAR-T therapies with lenzilumab, the companys proprietary Humaneered anti-human-GM-CSF immunotherapy, which is its lead product candidate.

CTI

Originally posted here:
Covington-based CTI partners with Humanigen for study of Lenzilumab for treatment of Coronavirus - User-generated content

Read More...

2020 Canada Gairdner Awards Recognize World-renowned Scientists for Transformative Contributions to Research That Impact Human Health – Yahoo Finance

Tuesday, March 31st, 2020

TORONTO , March 31, 2020 /CNW/ - The Gairdner Foundation is pleased to announce the 2020 Canada Gairdner Award laureates, recognizing some of the world's most significant biomedical research and discoveries. During these challenging times, we believe it is important to celebrate scientists and innovators from around the world and commend them for their tireless efforts to conduct research that impacts human health.

2020 Canada Gairdner International AwardThe five 2020 Canada Gairdner International Award laureates are recognized for seminal discoveries or contributions to biomedical science:

Dr. Masatoshi Takeichi Senior Visiting Scientist, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan ; Professor Emeritus, Kyoto University , Kyoto, Japan

Dr. Rolf Kemler Emeritus Member and Director, Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany

Awarded "For their discovery, characterization and biology of cadherins and associated proteins in animal cell adhesion and signalling."

Dr. Takeichi

The Work: The animal body is made up of numerous cells. Dr. Takeichi was investigatinghow animal cells stick together to form tissues and organs, and identified a key protein which he named 'cadherin'.Cadherin is present on the surface of a cell and binds to the same cadherin protein on the surface of another cell through like-like interaction, thereby binding the cells together. Without cadherin, cell to cell adhesion becomes weakened and leads to the disorganization of tissues. Dr. Takeichi found that there are multiple kinds of cadherin within the body, each of which are made by different cell types, such as epithelial and neuronal cells. Cells with the same cadherins tend to cluster together, explaining the mechanism of how different cells are sorted out and organized to form functional organs.

Further studies by Dr. Takeichi's group showed that cadherin function is supported by a number of cytoplasmic proteins, includingcatenins, and their cooperation is essential for shaping of tissues. His studies also revealed that the cadherin-dependent adhesion mechanism is involved in synaptic connections between neurons, which are important for brain wiring.

Dr. Kemler

The Work: Dr. Kemler, using an immunological approach, developed antibodies directed against surface antigens of early mouse embryos. These antibodies were shown to prevent compaction of the mouse embryo and interfered with subsequent development. Both Dr. Kemler and Dr. Takeichi went on to clone and sequence the gene encoding E-cadherin and demonstrate that it was governing homophilic cell adhesion.

Dr. Kemler also discovered the other proteins that interact with the cadherins, especially the catenins, to generate the machinery involved in animal cell-to-cell adhesion. This provided the first evidence of their importance in normal development and diseases such as cancer. It has been discovered that cadherins and catenins are correlated to the formation and growth of some cancers and how tumors continue to grow. Beta catenin is linked to cell adhesion through interaction with cadherins but is also a key component of the Wnt signalling pathway that is involved in normal development and cancer. There are approximately 100 types of cadherins, known as the cadherin superfamily.

Dr. Takeichi

The Impact: The discovery of cadherins, which are found in all multicellular animalspecies, has allowed us to interpret how multicellular systems are generated and regulated. Loss of cadherin function has been implicated as the cause of certain cancers, as well as in invasiveness of many cancers. Mutations in special types of cadherin result in neurological disorders, such as epilepsy and hearing loss. The knowledge of cadherin function is expected to contribute to the development of effective treatments against such diseases.

Dr. Kemler

The Impact: Human tumors are often of epithelial origin. Given the role of E-cadherin for the integrity of an epithelial cell layer, the protein can be considered as a suppressor of tumor growth. The research on the cadherin superfamily has had great impact on fields as diverse as developmental biology, cell biology, oncology, immunology and neuroscience. Mutations in cadherins/catenins are frequently found in tumors. Various screens are being used to identify small molecules that might restore cell adhesion as a potential cancer therapy.

Dr. Roel Nusse Professor & Chair, Department of Developmental Biology; Member, Institute for StemCell Biology andRegenerativeMedicine, Stanford University , School of Medicine. Virginia and Daniel K. Ludwig Professor of Cancer Research. Investigator, Howard Hughes Medical Institute

Awarded"For pioneering work on the Wnt signaling pathway and its importance in development, cancer and stem cells"

The Work: Dr. Nusse's research has elucidated the mechanism and role of Wnt signaling, one of the most important signaling systems in development. There is now abundant evidence that Wnt signaling is active in cancer and in control of proliferation versus differentiation of adult stem cells, making the Wnt pathway one of the paradigms for the fundamental connections between normal development and cancer.

Among Dr. Nusse's contributions is the original discovery of the first Wnt gene (together with Harold Varmus) as an oncogene in mouse breast cancer. Afterwards Dr. Nusse identified the Drosophila Wnt homolog as a key developmental gene, Wingless. This led to the general realization of the remarkable links between normal development and cancer, now one of the main themes in cancer research. Using Drosophila genetics, he established the function of beta-catenin as a mediator of Wnt signaling and the Frizzleds as Wnt receptors (with Jeremy Nathans ), thereby establishing core elements of what is now called the Wnt pathway. A major later accomplishment of his group was the first successful purification of active Wnt proteins, showing that they are lipid-modified and act as stem cell growth factors.

The Impact: Wnt signaling is implicated in the growth of human embryos and the maintenance of tissues. Consequently, elucidating the Wnt pathway is leading to deeper insights into degenerative diseases and the development of new therapeutics. The widespread role of Wnt signaling in cancer is significant for the treatment of the disease as well. Isolating active Wnt proteins has led to the use of Wnts by researchers world-wide as stem cell growth factors and the expansion of stem cells into organ-like structures (organoids).

Dr. Mina J. Bissell Distinguished Senior Scientist, Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory; Faculty; Graduate Groups in Comparative Biochemistry, Endocrinology, Molecular Toxicology and Bioengineering, University of California Berkeley , Berkeley, CA , USA

Awarded "For characterizing "Dynamic Reciprocity" and the significant role that extracellular matrix (ECM) signaling and microenvironment play in gene regulation in normal and malignant cells, revolutionizing the fields of oncology and tissue homeostasis."

The Work: Dr. Mina Bissell's career has been driven by challenging established paradigms in cellular and developmental biology. Through her research, Dr. Bissell showed that tissue architecture plays a dominant role in determining cell and tissue phenotype and proposed the model of 'dynamic reciprocity' (DR) between the extracellular matrix (ECM) and chromatin within the cell nucleus. Dynamic reciprocity refers to the ongoing, bidirectional interaction between cells and their microenvironment. She demonstrated that the ECM could regulate gene expression just as gene expression could regulate ECM, and that these two phenomena could occur concurrently in normal or diseased tissue.

She also developed 3D culture systems to study the interaction of the microenvironment and tissue organization and growth, using the mammary gland as a model.

The Impact:Dr. Bissell's model of dynamic reciprocity has been proven and thoroughly established since its proposal three decades ago and the implications have permeated every area of cell and cancer biology, with significant implications for current and future therapies. Dr. Bissell's work has generated a fundamental and translationally crucial paradigm shift in our understanding of both normal and malignant tissues.

Her findings have had profound implications for cancer therapy by demonstrating that tumor cells can be influenced by their environment and are not just the product of their genetic mutations. For example, cells from the mammary glands grown in two-dimensional tissue cultures rapidly lose their identity, but once placed in proper three-dimensional microenvironments, they regain mammary form and function. This work presages the current excitement about generation of 3D tissue organoids and demonstrates Dr. Bissell's creative and innovative approach to science.

Dr. Elaine Fuchs Howard Hughes Medical Institute Investigator and Rebecca C. Lancefield Professor and Head of the Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Cell Biology; The Rockefeller University , New York, NY , USA

Awarded"For her studies elucidating the role of tissue stem cells in homeostasis, wound repair, inflammation and cancer."

The Work: Dr. Fuchs has used skin to study how the tissues of our body are able to replace dying cells and repair wounds. The skin must replenish itself constantly to protect against dehydration and harmful microbes. In her research, Fuchs showed that this is accomplished by a resident population of adult stem cells that continually generates a shell of indestructible cells that cover our body surface.

In her early research, Fuchs identified the proteins---keratinsthat produce the iron framework of the skin's building blocks, and showed that mutations in keratins are responsible for a group of blistering diseases in humans. In her later work, Fuchs identified the signals that prompt skin stem cells to make tissue and when to stop. In studying these processes, Fuchs learned that cancers hijack the fundamental mechanisms that tissue stem cells use to repair wounds. Her team pursued this parallel and isolated and characterized the malignant stem cells that are responsible for propagating a type of cancer called "squamous cell carcinoma." In her most recent work, she showed that these cells can be resistant to chemotherapies and immunotherapies and lead to tumor relapse.

The Impact: All tissues of our body must be able to replace dying cells and repair local wounds. Skin is particularly adept at performing these tasks. The identification and characterization of the resident skin stem cells that make and replenish the epidermis, sweat glands and hair provide important insights into this fountain of youth process and hold promise for regenerative medicine and aging. In normal tissues, the self-renewing ability of stem cells to proliferate is held in check by local inhibitory signals coming from the stem cells' neighbours. In injury, stimulatory signals mobilize the stem cells to proliferate and repair the wound. In aging, these normal balancing cues are tipped in favour of quiescence. In inflammatory disorders, stem cells become hyperactivated. In cancers, the wound mechanisms to mobilize stem cells are hijacked, leading to uncontrolled tissue growth. Understanding the basic mechanisms controlling stem cells in their native tissue is providing new strategies for searching out refractory tumor cells in cancer and for restoring normalcy in inflammatory conditions.

2020 John Dirks Canada Gairdner Global Health AwardThe 2020 John Dirks Canada Gairdner Global Health Award laureate is recognized for outstanding achievements in global health research:

Professor Salim S. Abdool Karim Director of CAPRISA (Centre for the AIDS Program of Research in South Africa), the CAPRISA Professor in Global Health at Columbia University , New York and Pro Vice-Chancellor (Research) at the University of KwaZulu-Natal, Durban, South Africa

Professor Quarraisha Abdool KarimAssociate Scientific Director of CAPRISA, Professor in Clinical Epidemiology, Columbia University , New York and Professor in Public Health at the Nelson Mandela Medical School and Pro Vice-Chancellor (African Health) at the University of KwaZulu-Natal, Durban, South Africa

Awarded"For their discovery that antiretrovirals prevent sexual transmission of HIV, which laid the foundations for pre-exposure prophylaxis (PrEP), the HIV prevention strategy that is contributing to the reduction of HIV infection in Africa and around the world."

The Work: UNAIDS estimates that 37 million people were living with HIV and 1.8 million people acquired HIV in 2017. In Africa, which has over two thirds of all people with HIV, adolescent girls and young women have the highest rates of new HIV infections. ABC (Abstinence, Be faithful, and use Condoms) prevention messages have had little impact - due to gender power imbalances, young women are often unable to successfully negotiate condom use, insist on mutual monogamy, or convince their male partners to have an HIV test.

In responding to this crisis, Salim and Quarraisha Abdool Karim started investigating new HIV prevention technologies for women about 30 years ago. After two unsuccessful decades, their perseverance paid off when they provided proof-of-concept that antiretrovirals prevent sexually acquired HIV infection in women. Their ground-breaking CAPRISA 004 trial showed that tenofovir gel prevents both HIV infection and genital herpes. The finding was ranked inthe "Top 10 Scientific Breakthroughs of 2010" by the journal, Science. The finding was heralded by UNAIDS and the World Health Organization (WHO) as one of the most significant scientific breakthroughs in AIDS and provided the first evidence for what is today known as HIV pre-exposure prophylaxis (PrEP).

The Abdool Karims have also elucidated the evolving nature of the HIV epidemic in Africa , characterising the key social, behavioural and biological risk factors responsible for the disproportionately high HIV burden in young women. Their identification of the "Cycle of HIV Transmission", where teenage girls acquire HIV from men about 10 years older on average, has shaped UNAIDS policies on HIV prevention in Africa .

The impact: CAPRISA 004 and several clinical trials of oral tenofovir led tothe WHO recommending a daily tenofovir-containing pill for PrEP as a standard HIV prevention tool for all those at high risk a few years later. Several African countries are among the 68 countries across all continents that are currently making PrEP available for HIV prevention. The research undertaken in Africa by this South African couple has played a key role in shaping the local and global response to the HIV epidemic.

2020 Canada Gairdner Wightman AwardThe 2020 Canada Gairdner Wightman Award laureate is a Canadian scientist recognized for outstanding leadership in medicine and medical science throughout their career:

Dr. Guy Rouleau Director of the Montreal Neurological Institute-Hospital (The Neuro); Professor & Chair of the Department of Neurology and Neurosurgery, McGill University ; Director of the Department of Neuroscience, McGill University Health Center

Awarded "For identifying and elucidating the genetic architecture of neurological and psychiatric diseases, including ALS, autism and schizophrenia, and his leadership in the field of Open Science."

The Work: Dr. Rouleau has identified over 20 genetic risk factors predisposing to a range of brain disorders, both neurological and psychiatric, involving either neurodevelopmental processes or degenerative events. He has defined a novel disease mechanism for diseases related to repeat expansions that are at play in some of the most severe neurodegenerative conditions. He has significantly contributed to the understanding of the role of de novo variants in autism and schizophrenia. In addition, he has made important advances for various neuropathies, in particular for amyotrophic lateral sclerosis (ALS) where he was involved in the identification of the most prevalent genetic risk factors -which in turn are now the core of innumerable ALS studies worldwide.

Dr. Rouleau has also played a pioneering role in the practice of Open Science (OS), transforming the Montreal Neurological Institute-Hospital (The Neuro) into the first OS institution in the world. The Neuro now uses OS principles to transform research and careand accelerate the development of new treatments for patients through Open Access, Open Data, Open Biobanking, Open Early Drug Discovery and non-restrictive intellectual property.

The Impact: The identification of genetic risk factors has a number of significant consequences. First, allowing for more accurate genetic counselling, which reduces the burden of disease to affected individuals, parents and society. A revealing case is Andermann syndrome, a severe neurodevelopmental and neurodegenerative condition that was once relatively common in the Saguenay-Lac-St-Jean region of Quebec . Now this disease has almost disappeared from that population. Second, identifying the causative gene allows the development of treatments. For instance, his earlier work on a form of ALS linked to the superoxide dismutase-1 gene (SOD1) opened up studies which are now the focal point of phase 2 clinical studies showing great promise.

Byactingasalivinglabforthelast coupleofyears,TheNeuroisspearheading the practice of OpenScience (OS).TheNeurois alsoengagingstakeholdersacross Canadawiththegoal of formalizinganational OSallianceforthe neurosciences.Dr.Rouleau'sworkinOScontributesfundamentallytothetransformationoftheveryecosystemofsciencebystimulatingnewthinkingandfosteringcommunitiesofsharing.InspiredbyTheNeuro'svision,theglobalsciencecommunityisreflecting oncurrentresearchconventionsandcollaborativeprojects,andthemomentumforOSisgainingafootholdinorganizationsandinstitutionsinallcornersoftheearth.

About the Gairdner Foundation:

The Gairdner Foundation was established in 1957 by Toronto stockbroker, James Gairdner to award annual prizes to scientists whose discoveries have had major impact on scientific progress and on human health. Since 1959 when the first awards were granted, 387scientists have received a Canada Gairdner Award and 92 to date have gone on to receive the Nobel Prize.The Canada Gairdner Awards promote a stronger culture of research and innovation across the country through our Outreach Programs including lectures and research symposia. The programs bring current and past laureates to a minimum of 15 universities across Canada to speak with faculty, trainees and high school students to inspire the next generation of researchers. Annual research symposia and public lectures are organized across Canada to provide Canadians access to leading science through Gairdner's convening power.

http://www.gairdner.org

SOURCE Gairdner Foundation

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2020/31/c7291.html

Read more from the original source:
2020 Canada Gairdner Awards Recognize World-renowned Scientists for Transformative Contributions to Research That Impact Human Health - Yahoo Finance

Read More...

IP : Tissue Regenix Group plc – Update in relation to working capital position and impact of COVID-19 pandemic – Marketscreener.com

Tuesday, March 31st, 2020

Tissue Regenix Group (AIM:TRX) ('Tissue Regenix' or the 'Company') the regenerative medical devices company, today provides an update in relation to its working capital position and an initial assessment of the impact to its business following the outbreak of COVID-19.

Following the trading update announced on 22 January 2020, Tissue Regenix has successfully implemented various cost control measures, resulting in the Board's belief that the Company's available cash runway will now continue to support its working capital requirements until at least the end of the second week of May 2020.

As previously announced, the Board is endeavouring to secure necessary funding for the Company. The Board is encouraged by a number of ongoing discussions with potential investors which the Board is working to conclude in the near future. However, there is no guarantee that any such discussions will result in near-term funding being made available to the Company. Should this funding not be forthcoming before the Company's available cash runway expires (not expected by the Board to be before the end of the second week of May) then the Board will be required to take action to protect the interests of creditors and which, if necessary, is likely to result in a material reduction in any resulting value attributable to shareholders.

COVID-19

Further announcements will be made at the appropriate time.

For more Information

The person responsible for this announcement is, Gareth Jones, Interim CEO.

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

See more here:
IP : Tissue Regenix Group plc - Update in relation to working capital position and impact of COVID-19 pandemic - Marketscreener.com

Read More...

Global Regenerative Medicine Market 2019 Present Status and Future Opportunities by Major Companies Typs and Applications 2024 – The Fuel Fox

Tuesday, March 31st, 2020

The report on the Global Regenerative Medicine Market has been prepared after conducting a comprehensive research through a systematized methodology. These skills are useful for scrutinizing the market on the terms of outlined research guidelines. Mainly, global Regenerative Medicine market research report covers all the information about the target audience, manufactures, vendors, research papers, products and many more.

Request a sample of this report @ https://www.orbispharmareports.com/sample-request/13701

Keeping a focus on the overall market aspects, and perceptions, this report vastly covers profiles of the companies who have made it big in this particular field along with their sales data and other data. It also suggests the business models, innovations, growth and every information about the big manufacturers that will be present the future market estimates. Every market consists of set of manufacturers, vendors and consumers that gives a definition to the market, its each and every move, achievements. All these are the important subjects required to study the analysis of the global Regenerative Medicine market. It also includes the major market conditions across the globe such as the product profit, price, production, capacity, demand, supply, as well as market growth structure. In addition, this report offers significant data through the SWOT analysis, investment return data, and investment feasibility analysis.

Top Companies Analysis:

J & J (DePuy Synthes)MedtronicZimmerBiometStrykerAllergan(Acelity)MiMedx GroupOrganogenesisFujifilm Cellular DynamicsOsiris TherapeuticsVcanbioCCBCCytoriCelgeneVericel CorporationGuanhao BiotechMesoblastAMAG Pharmaceuticals (CBR)ViaCordCordLifeIntegra LifeSciencesNuvasiveCook BiotechJapan Tissue Engineering

Browse the complete report @ https://www.orbispharmareports.com/global-regenerative-medicine-market-2019-present-status-and-future-opportunities-by-major-companies-typs-and-applications-2024/

The global Regenerative Medicine market report also features a comprehensive quantitative and qualitative evaluation by analysing information collected from market experts and industry participants in the major points of the market value chain. The data offered in global Regenerative Medicine market report is gathered based on the latest industry news, trends, as well as opportunities. This study offers a separate analysis of the major trends in the existing market, mandates and regulations, micro & macroeconomic indicators is also comprised in this report. By doing so, the study estimated the attractiveness of every major segment during the prediction period.

Segmentation by Type:

Cell TherapyTissue EngineeringOthers

Segmentation by Application:

DermatologyCardiovascularCNSOrthopedicOthers

Moreover, the report comprises the analysis of opportunities available in the Regenerative Medicine market on the global level. It also includes the major market conditions across the globe such as the product profit, price, production, capacity, demand, supply, as well as market growth structure.The annual progression for the global Regenerative Medicine market in different regions cannot always be listed down as it will keep changing, thus studying and reviewing markets occasionally becomes vital. In addition, the Regenerative Medicine market report provides a detailed information about the key market players along with the strategies they implemented to gain market existence and develop themselves. The report includes precise market estimations depending on current market status and future market forecasts.

Make an enquiry of this report @ https://www.orbispharmareports.com/enquiry-before-buying/13701

About Us :

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us :

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199; +91 895 659 5155

Link:
Global Regenerative Medicine Market 2019 Present Status and Future Opportunities by Major Companies Typs and Applications 2024 - The Fuel Fox

Read More...

Page 25«..1020..24252627..3040..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick